Fact-checked by Grok 2 weeks ago

Tetanus

Tetanus is an acute, often fatal disease caused by an exotoxin known as tetanospasmin, which is produced by the anaerobic, gram-positive, spore-forming bacterium Clostridium tetani.^[1] This bacterium is ubiquitous in the environment, particularly in soil, dust, animal feces, and manure, where its resilient spores can survive for years.^[2] The infection occurs when spores enter the body through wounds or breaks in the skin, germinate under anaerobic conditions, and release the neurotoxin that travels to the central nervous system, blocking inhibitory neurotransmitters and leading to uncontrolled muscle contractions.^[1] Tetanus is not contagious and cannot be spread from person to person, making it distinct from many other bacterial infections.^[2] The clinical presentation of tetanus typically begins with an incubation period of 3 to 21 days after exposure, averaging about 8 days, during which symptoms emerge progressively.^[2] Generalized tetanus, the most common form accounting for over 80% of cases, starts with trismus (lockjaw due to masseter muscle stiffness) and generalized muscle rigidity, followed by painful spasms that can be triggered by stimuli like noise or touch.^[1] Other forms include localized tetanus, affecting muscles near the wound; cephalic tetanus, involving cranial nerves after head or neck injuries; and neonatal tetanus, a severe variant in newborns from unclean umbilical cord practices.^[1] Complications such as laryngospasm, fractures from spasms, autonomic instability, and respiratory failure contribute to a case-fatality rate of approximately 5% (2013–2022) even with modern care, with recovery potentially taking months.^[1]^[3] Epidemiologically, tetanus occurs worldwide but is rare in vaccinated populations, with the United States reporting 23 to 30 cases annually in recent years, primarily among unvaccinated or undervaccinated individuals.^[1] Risk factors include advanced age (especially over 80), diabetes, immunosuppression, injection drug use, and recent contaminated wounds from injuries, surgeries, or burns.^[2] Diagnosis is primarily clinical, based on history and symptoms, as laboratory confirmation via C. tetani culture is positive in only about 30% of cases and not required.^[1] Treatment involves immediate hospitalization, administration of human tetanus immune globulin to neutralize unbound toxin, thorough wound debridement, antibiotics like metronidazole, and supportive measures such as muscle relaxants, mechanical ventilation, and control of autonomic dysfunction.^[1] Prevention relies heavily on active immunization with tetanus toxoid-containing vaccines, which provide long-lasting immunity through a primary series in infancy and boosters every 10 years for adults.^[2] The vaccines—DTaP for children, Tdap for adolescents and adults (including during pregnancy), and Td for boosters—have dramatically reduced tetanus incidence since their introduction, eliminating neonatal tetanus in many regions.^[1] For wound management, post-exposure prophylaxis includes tetanus toxoid and/or immune globulin based on vaccination history and wound severity, emphasizing the importance of prompt cleaning and medical evaluation of injuries.^[1] Global efforts by organizations like the World Health Organization continue to target maternal and neonatal tetanus elimination through vaccination and hygiene improvements in high-risk areas.^[1]

Clinical Presentation

Incubation Period

The incubation period of tetanus refers to the time from wound inoculation with Clostridium tetani spores to the onset of symptoms, typically ranging from 3 to 21 days with an average of 8 to 10 days.^[4]^[5]^[6] Shorter incubation periods, particularly less than 7 days, are associated with more severe disease and higher mortality risk due to greater toxin production and faster progression.^[4]^[7] Several factors influence the duration of the incubation period. The distance of the wound from the central nervous system plays a key role, as the tetanospasmin toxin must travel via axonal transport to reach inhibitory neurons; wounds farther from the brain or spinal cord generally result in longer incubation times.^[4]^[7] Higher bacterial load or inoculum size at the wound site can shorten the period by accelerating toxin production.^[7] Prior immunization status also affects susceptibility, with unvaccinated or inadequately immunized individuals at higher risk of severe outcomes if infection occurs.^[4] Additionally, the incubation site matters; for example, head or neck wounds in cephalic tetanus can reduce the period to 1 to 2 days due to proximity to cranial nerves.^[4] Toward the end of the incubation period, early warning signs may emerge, such as mild muscle stiffness or trismus (lockjaw), signaling the impending onset of generalized tetanus symptoms like rigidity and spasms.^[7]

Generalized Tetanus

Generalized tetanus is the most common form of the disease, accounting for the majority of cases and characterized by widespread muscle rigidity and spasms due to the action of tetanospasmin toxin.^[7] It typically follows an incubation period of 3 to 21 days, with an average of 8 days, after which symptoms emerge progressively.^[4] Initial symptoms often begin with trismus, or lockjaw, resulting from spasms in the masseter muscles, alongside dysphagia due to pharyngeal muscle involvement and neck stiffness from rigidity in the cervical muscles.^[7] These early signs reflect the toxin's interference with inhibitory neurotransmitters, leading to unopposed muscle contractions.^[4] As the condition progresses, facial muscle rigidity produces risus sardonicus, a characteristic grimacing smile caused by contraction of the orbicularis oris.^[7] Generalized spasms then ensue, often triggered by sensory stimuli such as light, noise, or touch, culminating in opisthotonos—an severe arching of the back with hyperextension of the spine and legs, accompanied by flexion of the arms.^[7] These spasms intensify over the first 7 to 10 days, plateau for 7 to 14 days, and can become extremely painful, interfering with breathing and swallowing.^[8] Complications frequently include autonomic instability, manifesting as labile blood pressure, cardiac arrhythmias, and excessive sweating, alongside respiratory failure from laryngospasm, airway obstruction, or aspiration pneumonia.^[7] Even with modern intensive care, mortality rates range from 10% to 20%, with higher risks among older adults and those with delayed treatment.^[7]^[4] The acute phase of spasms typically lasts 3 to 4 weeks, requiring prolonged supportive care such as mechanical ventilation and muscle relaxants, after which a recovery phase begins involving gradual resolution of rigidity.^[7]^[8] Full recovery may take months, often leaving residual muscle weakness and fatigue due to the time needed for axonal regeneration and toxin clearance.^[7] Patients usually require 4 to 6 weeks of intensive care monitoring to manage these effects.^[8]

Specialized Forms

Specialized forms of tetanus, which deviate from the typical generalized presentation, include neonatal, local, and cephalic variants; these share the underlying pathophysiology of tetanospasmin toxin-mediated inhibition of neurotransmitter release but manifest in age- or site-specific ways.^[4] These forms collectively represent approximately 15-20% of cases in surveillance data from regions with robust reporting, such as the United States, though neonatal tetanus has historically comprised a larger proportion in low-resource settings before widespread vaccination efforts.^[9] Neonatal tetanus arises in newborns through infection of the umbilical stump, typically due to contamination during unhygienic delivery practices such as using nonsterile cutting instruments or applying unclean substances to the cord.^[5] Symptoms generally begin 3 to 14 days after birth, starting with an inability to suck or breastfeed, followed by excessive crying, muscle rigidity, and spasms.^[4] Global vaccination efforts have reduced neonatal tetanus incidence dramatically, with ~25,000 deaths in 2018 (a 97% decline since 1988) and elimination certified in many countries as of 2023.^[5] Without appropriate medical intervention, mortality rates approach 100%, primarily from respiratory failure and autonomic dysfunction, though intensive care can reduce this to 10-20%.^[10] Local tetanus is restricted to the muscles near the site of injury, producing milder, localized spasms and increased muscle tone without widespread involvement.^[7] This form carries a lower mortality risk compared to generalized tetanus, with case-fatality rates under 1% in treated patients, but it can progress to the more severe generalized type in some cases.^[11] Recovery is often prolonged, spanning months, and emphasizes the importance of prompt wound care and immunization. Cephalic tetanus typically develops following injuries to the head or ear, or in association with otitis media, leading to involvement of cranial nerves.^[12] It features flaccid palsies, such as facial weakness or ptosis, alongside trismus, with a notably rapid onset of 1 to 2 days post-injury.^[4] Prognosis is poor, with mortality rates of 15-30% even with treatment, as approximately two-thirds of cases advance to generalized tetanus, complicating management due to early cranial nerve compromise.^[13]

Etiology

Clostridium tetani

Clostridium tetani is a Gram-positive, spore-forming, obligate anaerobic rod-shaped bacterium that measures approximately 0.3 to 0.5 μm in width and 2 to 4 μm in length.^[7] It is motile, possessing peritrichous flagella that enable movement in liquid environments.^[14] In mature cultures, the bacterium may appear Gram-variable due to structural changes in its thick peptidoglycan cell wall.^[7] The vegetative cells are typically straight or slightly curved rods, but the most distinctive feature is the formation of terminal endospores, which swell the ends of the cells, giving them a characteristic "drumstick," "tennis racket," or "club-shaped" appearance under microscopic examination.^[7] The natural habitat of C. tetani includes soil, dust, and animal feces, where it persists primarily in its highly resilient spore form.^[15] These spores are ubiquitous in environments contaminated by intestinal contents of humans and animals, such as agricultural soils and manure.^[7] The spores exhibit extraordinary resistance to environmental stresses, including heat (surviving boiling for several minutes), chemical disinfectants like formalin and ethanol, desiccation, and freezing.^[7] They can remain viable and infectious in soil for over 40 years, contributing to the bacterium's widespread distribution and persistence without a true reservoir host.^[16] Infection occurs when C. tetani spores are introduced into the body through traumatic wounds, particularly deep puncture injuries contaminated with soil, dirt, or manure that create anaerobic conditions conducive to germination.^[7] Examples include nail punctures, crush injuries, or wounds from rusty objects, as well as non-traumatic sites like surgical incisions, burns, or umbilical stumps in neonates.^[15] Once germinated in low-oxygen tissues with necrotic or devitalized material, the bacteria multiply locally but remain non-invasive, confined to the wound site without disseminating systemically through the bloodstream or lymphatic system.^[17] This localized proliferation leads to the production of tetanospasmin, the potent neurotoxin responsible for tetanus symptoms.^[7]

Tetanospasmin Toxin

Tetanospasmin is a protein neurotoxin produced by the anaerobic, spore-forming bacterium Clostridium tetani, which serves as the causative agent of tetanus.^[18] The toxin is synthesized by vegetative cells during the late exponential growth phase following spore germination in anaerobic wound environments, with sporulation occurring subsequently.^[7] Its production is genetically encoded by the tetX gene, located on a large plasmid (pE88, approximately 74 kb) that also carries regulatory elements for toxin expression.^[19] The mature tetanospasmin molecule is a bipartite protein with a total molecular weight of 150 kDa, consisting of a heavy chain (approximately 100 kDa) responsible for receptor binding and cellular translocation, and a light chain (approximately 50 kDa) that harbors the enzymatic activity.^[20] These two chains are covalently linked by a single interchain disulfide bond, which maintains the toxin's structural integrity until proteolytic activation occurs extracellularly.^[21] This dichain configuration is typical of clostridial neurotoxins and enables the toxin's dual functionality in targeting neural tissues.^[22] Upon bacterial lysis or autolysis at the infection site, tetanospasmin is released as a soluble protein that diffuses locally from the wound.^[7] It then enters the lymphatic system and bloodstream, allowing systemic dissemination to peripheral nerve endings, particularly at neuromuscular junctions where it accumulates in sufficient quantities to exert its effects.^[7] This hematogenous and lymphatic spread occurs without direct bacterial invasion beyond the initial wound, distinguishing tetanus as a toxemia rather than a true infection.^[7] Tetanospasmin ranks among the most potent biological toxins known, with an estimated human lethal dose (LD₅₀) of approximately 2.5 ng/kg body weight when administered parenterally.^[1] This extreme toxicity underscores its minimal required amount for fatality—on the order of picograms for an average adult—highlighting the critical need for preventive vaccination strategies.^[1]

Pathophysiology

Neurospecific Binding

Tetanospasmin, the neurotoxin produced by Clostridium tetani, initiates its pathogenic action through neurospecific binding mediated primarily by its heavy chain. The C-terminal domain of the heavy chain recognizes and attaches to specific receptors on neuronal surfaces, including b-series gangliosides such as GD1b and GT1b, which serve as high-affinity lipid receptors enriched in neuronal membranes. These gangliosides facilitate the toxin's initial adhesion without causing immediate cellular disruption, positioning it for further interactions. Additionally, the heavy chain binds to proteinaceous receptors, notably nidogens (extracellular matrix glycoproteins) at the neuromuscular junction and synaptic vesicle glycoprotein 2 (SV2) isoforms A and B, which enhance specificity and uptake efficiency. Recent studies have identified receptor-type protein tyrosine phosphatases LAR and PTPRδ as additional receptors that interact with the nidogen-tetanus toxin complex via their immunoglobulin and fibronectin III domains, further facilitating neuronal uptake.^[23]^[24]^[25] This binding exhibits a marked preference for presynaptic terminals of motor neurons at neuromuscular junctions and autonomic synapses, where receptor densities are highest, rather than sensory neurons. The toxin's affinity for these sites allows it to enter the peripheral nervous system selectively, followed by retrograde axonal transport to the central nervous system. Once bound, tetanospasmin exploits the lipid raft domains of the neuronal plasma membrane, where gangliosides and glycoproteins colocalize, ensuring targeted adhesion.^[26]^[27]^[28] The binding process is influenced by environmental factors, including pH, with structural studies indicating that acidic conditions (below pH 6) promote conformational changes in the heavy chain that stabilize receptor interactions, potentially aiding attachment in inflamed or ischemic tissues near wound sites. This neurospecific attachment prepares the toxin for subsequent internalization via receptor-mediated endocytosis, without eliciting acute cytotoxicity at the binding stage.^[29]^[30]

Internalization and Translocation

Following binding to neuronal receptors such as gangliosides and synaptic vesicle protein 2 (SV2), tetanospasmin, also known as tetanus neurotoxin (TeNT), undergoes receptor-mediated endocytosis at the presynaptic membrane of motor neuron terminals. This process involves clathrin-dependent uptake into early endosomes, often via recycling synaptic vesicles, where the toxin-receptor complex is internalized as an intact holotoxin comprising a heavy chain (HC) and light chain (LC) linked by a disulfide bond. The endocytic vesicles then mature into late endosomes, a step essential for subsequent translocation.^[25]^[27]^[31] Within the acidified endosomal lumen, with pH dropping to approximately 5, the low pH induces a conformational change in the HC, enabling its translocation domain to insert into the endosomal membrane and form an ion-permeable pore or channel. This pore facilitates the reduction of the interchain disulfide bond, likely by host thioredoxin systems, allowing the LC—a zinc-dependent protease—to unfold and translocate across the membrane into the cytosol. Inhibitors of vacuolar ATPase, such as bafilomycin A1, block this acidification-dependent step, preventing LC entry and confirming its pH sensitivity. While some TeNT may translocate locally at peripheral synapses, the majority remains intact in signaling endosomes for further intracellular trafficking.^[27]^[31] The internalized TeNT is then transported retrogradely along axons via microtubule-based fast transport, powered by dynein motors, toward the central nervous system. This dual targeting enables action at both peripheral neuromuscular junctions and, more critically, inhibitory interneurons in the spinal cord, where the toxin disrupts inhibitory neurotransmission. Transport occurs at speeds of approximately 100–400 mm/day, consistent with fast retrograde axonal dynamics observed in vivo and in vitro.^[32] Upon reaching the spinal cord, TeNT may undergo transcytosis or interneuronal transfer to access its primary targets.^[25]^[33]

Enzymatic Cleavage of Targets

The light chain of tetanospasmin functions as a zinc-dependent metalloprotease that specifically cleaves synaptobrevin, also known as vesicle-associated membrane protein (VAMP)-2, within the SNARE complex essential for synaptic vesicle exocytosis. This enzymatic activity is facilitated by the toxin's translocation into the neuronal cytosol, where the light chain's active site, characterized by a His-Glu-X-X-His zinc-binding motif, catalyzes the proteolysis at the Gln76-Phe77 bond of VAMP-2. The specificity of this cleavage distinguishes tetanospasmin from related botulinum neurotoxins, targeting primarily VAMP isoforms in central inhibitory synapses.^[34]^[35]^[36] Cleavage of VAMP-2 disrupts the formation of the SNARE complex, which is required for the docking and fusion of synaptic vesicles with the presynaptic membrane, thereby preventing the exocytosis of vesicles containing inhibitory neurotransmitters. In spinal cord interneurons, this inhibition specifically blocks the release of glycine and γ-aminobutyric acid (GABA), the primary inhibitory transmitters that normally suppress motor neuron activity. As a result, the loss of inhibitory signaling leads to disinhibition of α-motor neurons, allowing unopposed excitatory input from upper motor neurons and interneurons to drive sustained muscle contraction.^[37]^[35]^[34] This proteolytic action is irreversible, as the cleaved VAMP-2 fragments cannot reassemble into functional SNARE complexes, and the degradation products are rapidly cleared from the synapse. Recovery from the toxin's effects thus depends on the de novo synthesis and incorporation of new VAMP-2 proteins into reformed SNARE complexes, a process that requires neuronal protein production and, in severe cases, axonal regeneration or synaptic remodeling, often taking weeks to months.^[36]^[35]

Diagnosis

Clinical Assessment

The clinical assessment of tetanus begins with a detailed patient history, focusing on potential exposure risks and early symptoms. A history of recent injury, such as a puncture wound, laceration, or contamination with soil or animal feces—even if minor or unnoticed—is a key risk factor, as the bacterium enters through such breaks in the skin. Incomplete or absent tetanus vaccination history, including lack of primary immunization or booster doses, significantly heightens suspicion in at-risk individuals. Symptoms typically emerge after an incubation period of 3 to 21 days, often presenting as progressive muscle stiffness and painful spasms without accompanying fever (unless secondary infection occurs) or sensory disturbances like numbness or paresthesia.^[4]^[5]^[38] The spatula test can provide supportive evidence for diagnosis. This simple bedside procedure involves touching the posterior pharynx with a tongue blade or spatula; in patients with tetanus, it elicits a reflex spasm of the masseter muscles, causing biting of the spatula, whereas normal individuals exhibit a gag reflex and attempt to expel it. The test has high sensitivity (94%) and specificity (100%).^[39]^[40] Physical examination emphasizes evaluation of neuromuscular function and autonomic stability. The hallmark sign is trismus, or lockjaw, characterized by spasm of the masseter muscles leading to inability to open the mouth more than 2 cm (measured as interincisal distance); this is often the initial manifestation in adults and older children. Generalized rigidity may follow, starting in the jaw and neck (risus sardonicus, a grimace-like facial expression), progressing to abdominal and limb muscles, with spasms readily elicited by sensory stimuli such as light, noise, or touch. Vital signs assessment reveals potential autonomic involvement, including tachycardia, labile hypertension, profuse sweating, and arrhythmias, indicating severe disease. These spasms arise from the inhibitory effects of tetanospasmin on neurotransmitter release in the central nervous system.^[12]^[41]^[42] Differential diagnosis requires exclusion of conditions mimicking tetanus's hypertonic spasms. Strychnine poisoning presents with similar generalized convulsions but features pronounced hyperreflexia and a shorter onset without preceding rigidity. Dystonic reactions, often drug-induced (e.g., from neuroleptics), cause focal spasms that respond rapidly to anticholinergics and lack the progressive nature of tetanus. Meningitis involves fever, headache, altered mental status, and nuchal rigidity, contrasting with tetanus's typical afebrile course and preserved consciousness.^[12]^[41] Tetanus is primarily a clinical diagnosis, lacking a single pathognomonic sign, but high clinical certainty is achieved through the combination of compatible history, characteristic spasms, and exclusion of alternatives in unvaccinated or wound-exposed patients. Early recognition is critical, as progression can be rapid and life-threatening.^[4]^[5]

Laboratory Confirmation

Laboratory confirmation of tetanus is challenging due to the absence of definitive diagnostic tests, with diagnosis relying primarily on clinical presentation; however, ancillary laboratory and imaging studies can provide supportive evidence and help exclude alternative conditions.^[4]^[7] Wound cultures may attempt to isolate Clostridium tetani from the site of injury, but this method has low diagnostic yield, positive in approximately 30% of cases, often due to prior antibiotic administration or the organism's sporulation state that hinders detection.^[39] A positive culture supports the diagnosis but is neither sensitive nor specific, as C. tetani can colonize wounds without causing disease, and negative results do not rule out tetanus.^[43] Anaerobic culture techniques are required, with incubation periods up to several days to detect toxigenic strains, though routine microbiology labs may not routinely perform toxigenicity testing.^[44] Serum antitoxin levels, measured via enzyme-linked immunosorbent assay (ELISA), assess protective immunity rather than active infection; levels below 0.1 IU/mL indicate susceptibility to tetanus, while ≥0.1 IU/mL are generally considered protective.^[1] In suspected cases, low or undetectable antitoxin titers corroborate lack of immunity but do not confirm ongoing toxemia, as toxin production occurs locally in tissues and circulating levels may not reflect disease activity.^[45] This test is more valuable for evaluating vaccination status pre- or post-exposure than for acute diagnosis.^[46] Electromyography (EMG) can demonstrate characteristic neuromuscular hyperactivity in tetanus, revealing continuous motor unit discharges, shortened or absent silent periods between bursts, and increased sensitivity to stimuli, which mimic tetanic contractions.^[39] These findings, observed during needle EMG of affected muscles, support the clinical suspicion by quantifying spasm patterns but are not pathognomonic, as similar abnormalities occur in conditions like stiff-person syndrome.^[47] EMG is particularly useful in atypical or localized presentations where clinical signs are subtle.^[48] Imaging modalities such as computed tomography (CT) or magnetic resonance imaging (MRI) of the brain and spine typically show no abnormalities in uncomplicated tetanus, as the pathology involves toxin-mediated neuronal dysfunction rather than structural lesions.^[39] These studies are employed primarily to rule out differentials like epidural abscesses, strokes, or mass lesions that could mimic tetanus symptoms, with normal results reinforcing the presumptive diagnosis when clinical features align.^[49] In rare cases of secondary complications, such as aspiration pneumonia, imaging may reveal pulmonary infiltrates, but this does not aid in confirming tetanus itself.^[50]

Prevention

Vaccination Strategies

The tetanus vaccine relies on tetanus toxoid (TT), an inactivated form of the tetanus toxin produced by Clostridium tetani, which stimulates the production of protective antibodies and antitoxins without causing infection. This toxoid is formulated into combination vaccines to enhance efficiency and coverage against multiple diseases: DTaP (diphtheria, tetanus, and acellular pertussis) for children under 7 years, Tdap (tetanus, diphtheria, and acellular pertussis) for adolescents and adults with a focus on pertussis protection, and Td (tetanus and diphtheria) for routine adult boosters without pertussis components. Each dose typically contains 5 to 10 flocculation units of tetanus toxoid, sufficient to induce long-lasting humoral immunity by prompting B-cell activation and memory cell formation.^[51]^[52] Standard immunization schedules aim to establish and sustain immunity from infancy through adulthood. The primary series for infants involves three doses of DTaP at 2, 4, and 6 months of age, followed by boosters at 15–18 months and 4–6 years to reinforce protection during early childhood. Adolescents receive a single Tdap dose at 11–12 years, transitioning to adult formulations. For adults, boosters with Td or Tdap are recommended every 10 years after completing the primary series, ensuring antibody levels remain above protective thresholds; a one-time Tdap dose is advised if not previously received. These protocols, developed by bodies like the CDC and WHO, have proven highly effective in preventing tetanus when adhered to.^[53]^[54] Maternal vaccination plays a critical role in safeguarding neonates, who are vulnerable due to an immature immune system and lack of prior exposure. Administering TT or Tdap during pregnancy—ideally between 27 and 36 weeks—transfers maternal antibodies across the placenta, providing passive immunity to the newborn for the first months of life. Global efforts, including targeted campaigns in high-risk areas, have achieved a 95% reduction in neonatal tetanus deaths over the past 30 years through such strategies.^[55] The World Health Organization's Expanded Programme on Immunization (EPI), initiated in 1974, has integrated tetanus toxoid into routine schedules worldwide, prioritizing DTP-containing vaccines to combat childhood diseases. By 2024, global coverage for the third dose of DTP reached 85%, averting millions of cases annually. However, significant gaps remain in low-income regions, where approximately 14.3 million infants miss the initial dose each year, often due to logistical challenges, conflict, and limited healthcare access in countries like Afghanistan, Nigeria, and Yemen; these disparities sustain tetanus as a persistent threat in underserved populations.^[56]

Wound Management and Prophylaxis

Wound management is a critical initial step in preventing tetanus following injury, focusing on reducing the bacterial load and creating an environment hostile to Clostridium tetani spore germination. Thorough cleaning of the wound with soap and water or saline irrigation is essential to remove dirt, debris, and potential contaminants, while surgical debridement should be performed to excise necrotic tissue and foreign material that could harbor spores.^[1] Antibiotics are not indicated for tetanus prophylaxis but may be prescribed if there is concern for other wound infections. High-risk wounds, including punctures, avulsions, crush injuries, burns, or those contaminated with soil, manure, or feces, require particularly aggressive care due to their anaerobic potential and likelihood of spore survival.^[57] Tetanus prophylaxis decisions depend on the wound classification and the patient's vaccination history, with the goal of providing both passive and active immunity where needed. For high-risk wounds in individuals who are unvaccinated (fewer than three prior doses of tetanus toxoid) or have unknown history, tetanus immune globulin (TIG) at a dose of 250 units intramuscularly is indicated to neutralize unbound toxin, often with part of the dose infiltrated around the wound if feasible.^[58] A booster dose of tetanus toxoid-containing vaccine (Td or Tdap) should also be given concurrently to initiate or complete active immunization.^[57] In contrast, clean minor wounds typically require only a toxoid booster if more than 10 years have elapsed since the last dose, assuming a complete primary series.^[1] For previously vaccinated individuals with high-risk wounds, a booster is recommended if the last dose was more than five years ago.^[57] Prophylactic measures are most effective when administered promptly after injury, ideally within 24 to 48 hours, as delays may reduce the ability to neutralize circulating toxin before it binds to neural tissue.^[57] Vaccination serves as the foundational protection, but post-exposure prophylaxis addresses immediate risks in potentially exposed individuals.^[59] Wounds should be left open or loosely packed to promote drainage and oxygenation, minimizing anaerobic conditions that favor tetanus development.^[60]

Treatment

Supportive Care

Supportive care forms the cornerstone of tetanus management, focusing on stabilizing patients, preventing complications, and maintaining vital functions in an intensive care setting. Patients with tetanus often require hospitalization in an ICU due to the risk of respiratory failure, autonomic instability, and prolonged muscle spasms, with treatment durations commonly extending 4-6 weeks. This approach emphasizes monitoring, symptom control, and environmental modifications to reduce mortality, which can reach 10-20% even with optimal care.^[8] Airway protection is critical, as laryngospasm and respiratory muscle spasms can lead to hypoxia and aspiration. In moderate to severe cases, endotracheal intubation followed by mechanical ventilation is frequently necessary, with approximately 50% of patients requiring this intervention to support breathing during spasms. Tracheostomy may be performed early to facilitate prolonged ventilation and reduce complications like ventilator-associated pneumonia.^[61]^[62] Sedation plays a key role in controlling tetanic spasms and rigidity, allowing for safer airway management and patient comfort. Benzodiazepines, particularly diazepam administered intravenously in high doses (up to 1000 mg/day in severe cases), are the mainstay for reducing spasm frequency and intensity without excessive respiratory depression. In ICU settings, neuromuscular blocking agents such as vecuronium are used alongside sedation to achieve full paralysis when spasms persist, often in conjunction with mechanical ventilation.^[62]^[63] Autonomic dysfunction, manifesting as labile hypertension, tachycardia, or arrhythmias, requires vigilant monitoring and targeted support to prevent cardiovascular collapse. Intravenous magnesium sulfate is commonly employed to mitigate spasms and stabilize autonomic instability by acting as a calcium antagonist and reducing catecholamine release, though it is not sufficient as monotherapy. Beta-blockers, such as labetalol or esmolol, are used for managing sympathetic overactivity, including hypertension and tachycardia, while avoiding agents that risk sudden cardiac events.^[64]^[62] Nutritional support and hygiene measures are essential to combat catabolism and prevent secondary issues during immobilization. Nasogastric tube feeding provides early enteral nutrition to meet high caloric demands and reduce aspiration risk, often starting immediately upon admission. Thrombosis prophylaxis with low-molecular-weight heparin is standard to counter deep vein thrombosis risk from prolonged bed rest, alongside measures like passive limb exercises. A quiet, dimly lit environment minimizes sensory stimuli that could trigger spasms, promoting overall stability.^[8]^[65]

Specific Interventions

The primary specific intervention for tetanus involves passive immunization with human tetanus immune globulin (HTIG) to neutralize unbound circulating tetanospasmin toxin produced by Clostridium tetani. HTIG is administered intramuscularly in doses ranging from 500 to 3000 international units (IU) as a single dose, depending on the severity of the disease and clinical guidelines; this binds free toxin in the bloodstream and tissues but cannot reverse toxin that has already attached to neuronal receptors.^[66]^[62] Recommendations vary, with the Centers for Disease Control and Prevention (CDC) endorsing 500 IU and the American Academy of Pediatrics suggesting up to 3000-6000 IU for generalized tetanus, reflecting uncertainty about the optimal dose but emphasizing early administration to limit progression.^[67]^[68] Since tetanus infection does not confer immunity, a tetanus toxoid-containing vaccine (such as Td or Tdap, depending on age and prior vaccination history) should be administered during convalescence to initiate or continue active immunization, typically starting 2 to 4 weeks after the acute phase or as per standard schedules.^[66] To eradicate the causative bacteria and halt further toxin production, antibiotics targeting anaerobic spore-forming organisms are initiated promptly. Metronidazole is the first-line agent, dosed at 500 mg intravenously every 6 hours for 7 to 10 days, as it effectively penetrates tissues and inhibits C. tetani without the neuromuscular blocking risks associated with penicillin in high doses.^[69]^[70] Alternative options like penicillin G may be used if metronidazole is unavailable, but metronidazole is preferred due to comparable efficacy and a lower risk of adverse effects in tetanus patients.^[64] Surgical wound debridement is a critical intervention when an identifiable wound is present, involving thorough excision of necrotic tissue, devitalized material, and foreign bodies to remove bacterial spores and reduce the anaerobic environment conducive to C. tetani proliferation. This procedure should be performed as soon as possible after diagnosis, often under controlled conditions to minimize spasms, and is essential even if the wound appears minor, as it directly addresses the source of infection.^[69]^[62] For severe tetanus cases refractory to standard therapy, intrathecal administration of TIG (typically 250-1000 IU) has been explored as an adjunct to deliver antitoxin directly to the central nervous system, potentially neutralizing toxin in the spinal fluid. However, its use remains controversial due to limited high-quality evidence, with meta-analyses showing inconsistent benefits over intramuscular routes and concerns about formulation safety for intrathecal injection in some regions.^[71]^[67] These targeted measures complement supportive care for muscle spasms but focus solely on toxin neutralization and bacterial elimination.^[69]

Epidemiology

Global Distribution

Tetanus remains a significant public health concern globally, with an estimated 73,662 cases occurring in 2019, according to Global Burden of Disease data.^[72] This represents an approximately 88% decline in total incidence since 1990, largely attributable to widespread vaccination programs that have boosted immunity in populations worldwide, while neonatal tetanus deaths have declined by 95% over the same period.^[55] Despite this progress, the disease persists in areas with limited access to healthcare and immunization, underscoring ongoing disparities in global health infrastructure. High-burden regions are concentrated in sub-Saharan Africa and South Asia, where environmental factors and incomplete vaccination coverage sustain transmission.^[73] In these areas, neonatal tetanus—often linked to unhygienic delivery practices—has been nearly eliminated in many countries through targeted interventions, with 47 of 59 priority nations achieving maternal and neonatal tetanus elimination status by 2020.^[74] By 2022, this figure rose to 80% of priority countries, and as of December 2024, 49 of 59 priority countries have achieved elimination status, reflecting sustained efforts in clean delivery and maternal immunization.^[75]^[76] In contrast, incidence rates in well-vaccinated populations are extremely low, typically below 1 case per million people. For instance, the United States reports around 30 cases annually, while Europe reported 73 cases in 2023, primarily due to high diphtheria-tetanus-pertussis (DTP) vaccine uptake exceeding 90% in most countries.^[77]^[78] Current trends emphasize the elimination of maternal and neonatal tetanus as a priority, with global strategies focusing on closing immunization gaps in high-risk districts. Among adults, cases increasingly occur from injuries in elderly individuals who lack booster vaccinations, particularly those over 65 years old in high-income settings where waning immunity poses a risk.^[79]^[80]

Risk Factors and Trends

Tetanus risk is primarily associated with incomplete or absent vaccination, which leaves individuals susceptible to infection from Clostridium tetani spores entering through wounds.^[5] Contaminated wounds, particularly puncture injuries, crush wounds, burns, or surgical sites exposed to dirt, feces, or saliva, serve as entry points, with heightened vulnerability in immunocompromised individuals, those with diabetes, and the elderly due to waning immunity and slower wound healing.^[15]^[2] Injection drug use further elevates risk through non-sterile needle punctures contaminated with soil or feces, accounting for a notable proportion of cases in affected populations.^[4] Disaster settings, such as earthquakes or floods, exacerbate these dangers by increasing the incidence of open wounds in unsanitary conditions, often compounded by disrupted healthcare access.^[81] Demographically, tetanus disproportionately affects adult males over 60 years, where incidence is elevated due to occupational exposures like farming or construction and lower vaccination booster rates, with global burden studies showing significantly higher rates in males overall.^[72]^[9] Among neonates, risk is greatest in low-resource settings with home deliveries lacking clean practices, where unclean cutting of the umbilical cord or application of substances like dung or ash introduces spores, contributing to nearly all remaining neonatal cases in unvaccinated mothers.^[82]^[83] These patterns highlight how socioeconomic factors, including limited access to maternal tetanus toxoid vaccination, perpetuate vulnerability in underserved communities. In the 2020s, global tetanus incidence has continued a marked decline, driven by expanded immunization programs supported by the GAVI Alliance, which has bolstered tetanus toxoid-containing vaccine coverage in low-income countries, reducing neonatal cases by over 89% since 2000.^[5]^[75] Globally, total reported cases declined from approximately 209,000 in 2015 to 73,662 in 2019, with neonatal cases around 27,000 in 2019, reflecting broader vaccination gains despite COVID-19 disruptions.^[72]^[73] Projections indicate that sustaining coverage above 90% for diphtheria-tetanus-pertussis vaccines could limit total cases to under 10,000 annually by 2030, aligning with Immunization Agenda 2030 goals.^[84] Outbreaks remain a concern in crisis scenarios, as seen after the 2010 Haiti earthquake, where over 230,000 deaths and widespread injuries led to tetanus cases from contaminated wounds amid overwhelmed health systems.^[81] Similarly, ongoing conflicts in regions like South Sudan and Somalia disrupt vaccination campaigns and increase wound risks, sustaining localized surges despite global progress.^[85]

Veterinary Aspects

Occurrence in Animals

Tetanus, caused by the neurotoxin tetanospasmin produced by Clostridium tetani, affects a wide range of animal species, though susceptibility varies significantly by taxonomy and physiology.^[86]^[87] The bacterium's spores, ubiquitous in soil and animal feces, enter through wounds under anaerobic conditions, leading to spastic paralysis without direct transmission between hosts.^[86]^[87] Herbivores such as horses, cattle, sheep, and goats are highly susceptible, with horses being the most affected domestic species.^[86]^[87] Infection typically occurs via deep puncture wounds, surgical procedures like castration or tail docking, or management practices such as ear tagging in sheep flocks.^[86]^[87]^[88] Clinical signs include progressive muscle stiffness, tremors, a characteristic "sawhorse" stance in horses, hypersensitivity, and eventual recumbency, often culminating in respiratory failure.^[86]^[89]^[90] Mortality rates range from 50% to 80%, with unvaccinated horses facing up to 80% lethality despite treatment.^[86]^[90]^[91] In carnivores and omnivores like dogs and cats, tetanus is rarer due to greater physiological resistance, though cases arise from bite wounds, fights, or postoperative infections.^[86]^[92]^[93] These species often exhibit localized (focal) tetanus, with spasms confined to the affected region, or generalized forms with milder stiffness and spasms compared to herbivores; incubation periods may extend longer.^[86]^[92] Mortality in dogs averages around 50%, lower than in more susceptible species.^[86] Poultry and birds generally show high resistance to tetanus toxin owing to a mutation in the VAMP protein cleavage site, rendering them largely unaffected even at high doses.^[94]^[95] In fish, such as goldfish, experimental exposure demonstrates toxin sensitivity and lethality under controlled conditions, but natural occurrences in aquaculture are undocumented and presumed negligible.^[96] The zoonotic potential of tetanus is low, as C. tetani does not spread directly from animals to humans; however, infected animals serve as environmental reservoirs, perpetuating spore contamination in soil and feces that indirectly sustains human risk.^[87]^[97]^[98]

Zoonotic and Agricultural Implications

Tetanus, caused by the bacterium Clostridium tetani, poses an indirect zoonotic risk to humans primarily through environmental contamination rather than direct animal-to-human transmission. The spores of C. tetani are ubiquitous in soil and animal feces, and human infection typically occurs when these spores enter wounds contaminated by animal products, such as manure or hides during farming activities. Direct transmission between animals and humans is rare and unsupported by evidence, as the disease requires spore inoculation into anaerobic wound environments rather than person-to-person or animal-to-person spread. In rural and agricultural settings, this indirect exposure heightens vulnerability for farmers handling livestock or working in spore-rich environments. In agriculture, tetanus inflicts significant economic losses on livestock operations due to high mortality rates in affected animals, particularly in species like horses and sheep, which are highly susceptible. Outbreaks can lead to severe financial impacts from animal deaths, treatment costs, and disrupted productivity, with cattle experiencing relatively rare but devastating herd losses during events like calving or castration. Prevention through herd vaccination is a cornerstone strategy; for instance, horses require annual tetanus toxoid boosters to maintain immunity, as recommended by equine health guidelines, reducing incidence and associated costs in equestrian and farming enterprises. Management of tetanus in agricultural contexts emphasizes both prophylactic and supportive measures to mitigate outbreaks. Tetanus antitoxin is administered to non-immunized animals following high-risk procedures, such as wounds or surgeries, to neutralize circulating toxin and prevent clinical progression. Hygiene practices are critical, including the use of sterile instruments, disinfection of wounds, and clean procedures during animal handling to minimize spore introduction—such as iodizing castration tools or maintaining sanitary calving areas. These interventions, combined with routine vaccination, help curb disease spread in farm settings. The One Health approach integrates animal vaccination and hygiene into broader public health strategies to reduce human tetanus exposure, particularly in rural areas where shared environments amplify risks. By vaccinating livestock herds, agricultural practices can lower overall spore dissemination from infected or deceased animals, thereby protecting farmers and communities from indirect contamination. This interdisciplinary framework underscores the interconnectedness of animal health, environmental management, and human immunization in preventing tetanus.

History

Early Recognition

The earliest descriptions of tetanus appear in ancient medical texts, where the condition was recognized through its characteristic muscle spasms following traumatic injuries. In the 5th century BCE, Hippocrates documented cases of opisthotonos—severe arching of the back due to spasms—occurring after wounds, noting symptoms such as lockjaw (trismus) and risus sardonicus, the grimacing facial expression caused by facial muscle rigidity.^[99] Similarly, in ancient India around 600 BCE, the Sushruta Samhita described apatantraka, a form of tetanus linked to vata dosha imbalance from penetrating wounds or trauma, with symptoms including body stiffness, convulsions, and upward gazing eyes, emphasizing its traumatic origin.^[100] These accounts highlighted the disease's association with injuries but lacked understanding of its microbial cause, often attributing it to humoral imbalances or divine punishment. By the 19th century, clinical observations in military settings further illuminated tetanus's severity, particularly through the term "lockjaw" for its hallmark jaw muscle contraction. During the American Civil War (1861–1865), tetanus afflicted wounded soldiers exposed to contaminated soil and debris, with approximately 505 cases reported and a mortality rate of around 90%, underscoring its lethality in unsanitary conditions.^[101] In 1884, German physician Arthur Nicolaier advanced etiological knowledge by isolating Clostridium tetani from soil samples and inducing tetanus-like symptoms in experimental animals, providing the first evidence of its bacterial origin.^[102] This work, building on earlier demonstrations by Antonio Carle and Giorgio Rattone of the disease's transmissibility via wound inoculation, shifted recognition from a mere "nervous" affliction to an infectious process mediated by a soil-borne pathogen.^[99] Early interventions focused on symptomatic relief rather than causation, as the infectious nature was only emerging. Curare, a South American plant-derived paralytic agent, was introduced in the mid-19th century by George Harley, who demonstrated its ability to relax rigid muscles and alleviate spasms in tetanus patients, though it carried risks of respiratory failure.^[103] Chloroform inhalation was similarly employed to sedate patients and control convulsions, as noted in late-19th-century military and civilian practices, offering temporary respite but not addressing the underlying toxin.^[104] The term "tetanus" itself derives from the Greek tetanos, meaning "to stretch" or "rigid," reflecting the observed muscle tension since antiquity.^[99] Tetanus's global toll was starkly evident in wartime, where wound contamination amplified its impact despite growing awareness. In World War I (1914–1918), despite improved wound care, tetanus caused significant casualties among Allied forces, with an overall case mortality rate of about 50%, often due to delayed prophylaxis in trench warfare environments rich in manure and soil.^[104] These high fatalities drove urgent research into prevention, marking the transition from empirical recognition to targeted medical responses.

Vaccine Development and Etymology

The development of tetanus antitoxin marked a pivotal advancement in the late 19th century, pioneered by Emil von Behring and Shibasaburo Kitasato in 1890 through their seminal experiments demonstrating passive immunization in animals using serum from immunized horses.^[105]^[106] This equine-derived antitoxin provided short-term protection, lasting weeks, and was first applied prophylactically in humans by 1897, as shown by Edmond Nocard's work on passive immunity transfer.^[99] Building on this, Gaston Ramon refined toxin inactivation techniques in the early 1920s, leading Pierre Descombey to create the first tetanus toxoid vaccine in 1924 by treating the toxin with formaldehyde to render it non-toxic while preserving immunogenicity.^[107]^[108] The tetanus toxoid gained widespread military application during World War II, where routine immunization of U.S. and Allied forces dramatically reduced incidence; only 12 cases occurred among over 12 million U.S. troops, representing a 95% decrease compared to World War I rates without vaccination.^[109] In the 1940s, the toxoid was combined with diphtheria and pertussis components to form the DTP vaccine, licensed in 1948 for routine childhood use, enhancing efficiency in immunization programs.^[110] Further evolution occurred in 2005 with the approval of Tdap vaccines—tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis—for adolescents and adults, addressing waning immunity and pertussis resurgence.^[111] Since 1974, the World Health Organization's Expanded Programme on Immunization has integrated tetanus toxoid into global efforts, particularly targeting maternal and neonatal tetanus elimination through campaigns vaccinating pregnant women.^[112] By the 1950s, widespread vaccination in developed nations led to near-elimination of tetanus in immunized populations, with U.S. cases dropping over 92% from pre-vaccine eras due to routine childhood dosing and boosters.^[113] The term "tetanus" derives from the Ancient Greek tetanos, meaning "rigid" or "tense," reflecting the characteristic muscle spasms, while "trismus"—describing the initial jaw lockjaw—is from Greek trismos, denoting "a grinding" or "gnashing of teeth."^[114] The tetanus toxin, identified as tetanospasmin, was further characterized in 1897 by Bruschettini, who demonstrated its retrograde axonal transport and central nervous system effects.^[26]

Research Directions

Novel Therapeutics

Emerging therapeutics for tetanus aim to address limitations in current antitoxin options and muscle spasm management, building on standard supportive care that includes tetanus immune globulin (TIG), antibiotics, and mechanical ventilation.^[7] Humanized monoclonal antibodies targeting tetanospasmin represent a promising alternative to equine-derived TIG, which carries risks of hypersensitivity reactions. Siltartoxatug, a recombinant human monoclonal antibody, demonstrated non-inferior efficacy to plasma-derived TIG in neutralizing tetanus toxin in a phase 3 randomized, double-blind trial involving patients with tetanus-prone wounds, with a lower incidence of adverse events such as anaphylaxis.^[115] This first-in-class therapy, developed using proprietary platforms, met its primary endpoint for passive immunization and is positioned to improve accessibility in resource-limited settings by avoiding the need for cold-chain storage required for TIG.^[116] It was approved for marketing by China's National Medical Products Administration (NMPA) in June 2025.^[117] Earlier phase 2 trials, such as those evaluating TNM002, confirmed safety and comparable neutralizing antibody titers to TIG in healthy volunteers, supporting its potential to replace heterologous antitoxins with reduced side effects.^[118] Research into botulinum toxin and its derivatives explores targeted inhibition of neurotransmitter release to counteract tetanus-induced spasms, leveraging the toxin's ability to cleave SNAP-25 and block acetylcholine at neuromuscular junctions, in contrast to tetanospasmin's inhibition of inhibitory interneurons.^[119] Preclinical studies in animal models highlight this mechanistic opposition, where botulinum neurotoxin A reduces excitatory muscle activity without the systemic spread seen in tetanus toxin.^[119] Clinical case reports demonstrate efficacy in managing localized spasms, such as trismus, with injections into masseter and temporalis muscles alleviating rigidity within 1-4 days and reducing reliance on systemic sedatives; for instance, early administration in severe cases shortened mechanical ventilation duration.^[120] Although no large-scale trials exist, these findings suggest analogs engineered for safer, muscle-specific delivery could offer adjunctive relief in refractory cases, pending further preclinical optimization.^[121] Neuromodulators provide options for controlling refractory spasms when conventional sedation fails. Intrathecal baclofen, delivered via implantable pumps, effectively suppresses extensor spasms in severe tetanus by activating GABA-B receptors in the spinal cord, as evidenced in pediatric cases where it facilitated weaning from ventilators and preserved mental status despite high-dose requirements.^[122] In a 12-year-old patient with spasms unresponsive to diazepam and vecuronium, intrathecal boluses reduced spasm frequency within hours, allowing dose reductions in paralytics and shorter ICU stays.^[123] Similarly, ketamine infusions offer sedation with analgesic properties, modulating NMDA receptors to dampen hyperexcitability; evidence from case series shows continuous infusions (e.g., 50 mcg/kg/hour) controlling spasms in generalized tetanus when combined with benzodiazepines, with minimal respiratory depression compared to other agents.^[64]^[124] Development of these therapeutics faces significant hurdles due to tetanus's status as a rare disease in high-income countries, qualifying it for orphan drug designations that incentivize research but struggle with limited commercial viability.^[125] Low incidence in vaccinated populations reduces funding opportunities, as global deaths—estimated at under 50,000 annually—concentrate in resource-poor settings where infrastructure for trials is inadequate.^[126] This orphan-like profile exacerbates access disparities, prioritizing innovations adaptable to low-resource environments, such as heat-stable monoclonal antibodies, over costly neuromodulator devices.^[127]

Vaccine Innovations

Recent advancements in tetanus vaccination focus on enhancing stability, ease of administration, and broader protective coverage to address challenges in global immunization, particularly in resource-limited settings. Innovations in toxoid formulations aim to improve heat resistance and immunogenicity, while alternative delivery routes and combination products seek to simplify vaccination schedules and protect vulnerable populations like neonates.^[128] Next-generation tetanus toxoids incorporate recombinant proteins to achieve greater stability and heat resistance, reducing reliance on cold-chain infrastructure. For instance, recombinant forms of tetanus toxoid, such as the 8MTT variant, have demonstrated comparable immunogenicity to traditional carriers when used in glycoconjugate vaccines, with potential for improved potency in preclinical evaluations.^[129] Additionally, encapsulation techniques using metal-organic frameworks (MOFs) have shown that tetanus toxoid can retain over 80% stability at 40°C for months and at 60°C for weeks, enabling storage without refrigeration in high-temperature environments.^[130] These developments build on historical vaccine efficacy rates exceeding 95% with standard toxoids, but offer practical advantages for deployment in tropical regions like India, where trials of enhanced formulations were reported in 2024. Mucosal vaccine formulations represent a promising shift toward needle-free delivery, with nasal and oral routes simplifying administration in field settings. Research into mucosal tetanus toxoid vaccines has explored safety and immunogenicity, though further clinical validation is needed.^[131] ^[132] These approaches could enhance compliance in mass campaigns by bypassing injections and targeting respiratory entry points for pathogens. Universal booster strategies emphasize combination vaccines to expand coverage against multiple diseases. The Tdap-IPV formulation, which includes tetanus toxoid, reduced diphtheria toxoid, acellular pertussis, and inactivated poliovirus, provides comprehensive protection in a single dose and is recommended for adolescents and adults to maintain immunity.^[52] Maternal vaccination with Tdap during pregnancy, ideally at 27-36 weeks gestation, transfers antibodies to newborns, significantly reducing neonatal tetanus risk by up to 90% in endemic areas.^[133]^[128] Global initiatives are exploring mRNA platforms for tetanus vaccines, leveraging post-COVID technologies for rapid development and adaptability. Preclinical studies in 2024 have evaluated multivalent mRNA-DTP vaccines, showing robust humoral and cellular responses in animal models, including protection against tetanus toxin challenge.^[134] These efforts align with the World Health Organization's Immunization Agenda 2030, targeting at least 90% coverage for the third dose of diphtheria-tetanus-pertussis vaccine globally to eliminate maternal and neonatal tetanus.^[135]

References

[1]
Chapter 21: Tetanus | Pink Book - CDC
Apr 25, 2024 · Tetanus is an acute, often fatal, disease caused by an exotoxin produced by the bacterium Clostridium tetani.
[2]
About Tetanus - CDC
May 30, 2025 · Tetanus is an infection caused by bacteria called Clostridium tetani (C. tetani), that are found in the environment.
[3]
Clinical Overview of Tetanus - CDC
Jun 10, 2025 · Tetanus is an uncommon but serious infection caused by bacteria found in the environment. The best way to prevent tetanus is to get vaccinated.
[4]
Tetanus - World Health Organization (WHO)
Jul 12, 2024 · The incubation period of tetanus varies between 3 and 21 days after infection. Most cases occur within 14 days. Symptoms can include: jaw ...
[5]
Tetanus - Symptoms and causes - Mayo Clinic
Dec 21, 2023 · The incubation period can range from 3 to 21 days. The most common type of tetanus is called generalized tetanus.Missing: influencing | Show results with:influencing
[6]
Tetanus (Clostridium tetani Infection) - StatPearls - NCBI Bookshelf
Feb 26, 2024 · Adverse prognostic factors include an incubation period of fewer than 48 hours, addiction to narcotics, the presence of generalized tetanus, a ...
[7]
Intensive Care Management of Severe Tetanus - PubMed Central
Patients with tetanus usually require 4–6 weeks of intensive care. Careful monitoring and adherence to protocolized care help reduce mortality.Clinical Features · Management Of Tetanus · Table 2
[8]
Tetanus Surveillance --- United States, 1998--2000 - CDC
The case-fatality ratio was 18% among 113 patients with known outcome; 75% of the deaths were among patients aged >60 years. No deaths occurred among those who ...
[9]
[PDF] Neonatal Tetanus - World Health Organization (WHO)
Sep 5, 2018 · In NT, symptoms appear 3 to 28 days after birth, averaging 7 days. The first sign of tetanus in a neonate is usually an inability to suck or ...
[10]
[PDF] Weekly epidemiological record Relevé épidémiologique ...
Dec 5, 2016 · Case-fatality rates for localized teta- nus are <1%.17. Cephalic tetanus is a rare form of the disease associated with ear infections (otitis ...
[11]
Clinical Features of Tetanus - CDC
Jun 10, 2025 · There are three forms of tetanus: Generalized; Localized; Cephalic. Generalized. Generalized tetanus is the most common form of the disease.
[12]
Cephalic Tetanus: A Case Report - PMC - NIH
About two-thirds of cephalic tetanus cases progress to generalised tetanus with bad prognosis [11]. In those who do not progress to generalized tetanus, the ...
[13]
Major pathogenic Clostridia in human and progress toward the ... - NIH
C. tetani is motile by peritrichous flagella (19). On sheep blood agar, it forms gray, rough colonies with alpha hemolysis, followed by beta hemolysis.
[14]
Tetanus: Causes and How It Spreads - CDC
Jun 10, 2025 · Spores of Clostridium tetani are common in the environment, including soil, dust, and manure. The spores develop into bacteria when they enter the body.
[15]
Tetanus: MedlinePlus Medical Encyclopedia
Dec 31, 2023 · In the spore form, C tetani can remain inactive in the soil. But it can remain infectious for more than 40 years.
[16]
Clostridia: Sporeforming Anaerobic Bacilli - Medical Microbiology
Tetanus and Clostridium Tetani. Clinical Manifestations. Tetanus is ... does not spread to healthy, undamaged tissue. Clostridial cellulitis has a more ...
[17]
Tetanus Toxin Synthesis is Under the Control of A Complex Network ...
Clostridium tetani produces a potent neurotoxin, the tetanus toxin (TeNT), which is responsible for an often-fatal neurological disease (tetanus) ...Missing: Tetanospasmin tetX
[18]
The genome sequence of Clostridium tetani, the causative agent of ...
The causative agent of tetanus disease is Clostridium tetani, an anaerobic spore-forming bacterium, whose natural habitat is soil, dust, and intestinal tracts ...
[19]
Tetanospasmin - an overview | ScienceDirect Topics
As with botulinum toxin, tetanus toxin is produced as a 150-kD precursor protein with a light (50 kD) and heavy chain (100 kD) linked via disulfide bonds. The ...
[20]
Novel neutralizing human monoclonal antibodies against tetanus ...
Jun 9, 2021 · The active form of TeNT consists of a light chain (Lc, also called fragment A, 50 kDa) and a heavy chain (100 kDa) linked by a disulfide bond, ...Missing: Tetanospasmin tetX
[21]
Tetanospasmin - an overview | ScienceDirect Topics
It is characterized by a heavy chain (100 kDa) and a light chain (50 kDa) connected by a disulfide bridge (Matsuda, 1989). Tetanospasmin is encoded on a plasmid ...Missing: tetX | Show results with:tetX
[22]
Gangliosides as High Affinity Receptors for Tetanus Neurotoxin - PMC
PC12 cells are enriched in b-series gangliosides GD1b, GT1b, and GQ1b and express low levels of a-series ganglioside Fuca-GM1a but do not express GD1a (22, 23).Missing: tetanospasmin | Show results with:tetanospasmin
[23]
Tetanus toxin entry. Nidogens are therapeutic targets for ... - PubMed
Nov 28, 2014 · Here, we show that the presence of nidogens (also known as entactins) at the NMJ is the main determinant for TeNT binding.
[24]
SV2 Mediates Entry of Tetanus Neurotoxin into Central Neurons - PMC
Nov 24, 2010 · The findings reported here indicate that SV2A and SV2B mediate binding and entry of tetanus neurotoxin into central neurons.Missing: tetanospasmin | Show results with:tetanospasmin
[25]
Tetanus Toxin - an overview | ScienceDirect Topics
At the neuromuscular junction, tetanus toxin binds to presynaptic nerve terminals because its neuronal receptors are enriched at synapses.39 As noted earlier, ...Missing: GD1b | Show results with:GD1b
[26]
Tetanus and botulinum neurotoxins: mechanism of action and ...
Tetanus neurotoxin (TeNT) binds to the presynaptic membrane of the neuromuscular junction, is internalized and transported retroaxonally to the spinal cord.Missing: GD1b | Show results with:GD1b
[27]
Tetanus toxin is internalized by a sequential clathrin-dependent ...
Jul 31, 2006 · These observations suggest that even though GD1b and other b-series gangliosides are essential for TeNT binding to the neuronal surface and ...
[28]
The structure of the tetanus toxin reveals pH‐mediated domain ...
Jun 23, 2017 · The tetanus neurotoxin (TeNT) is a highly potent toxin produced by Clostridium tetani that inhibits neurotransmission of inhibitory interneurons.Missing: wound | Show results with:wound
[29]
SV2 Mediates Entry of Tetanus Neurotoxin into Central Neurons
The findings reported here indicate that SV2A and SV2B mediate binding and entry of tetanus neurotoxin into central neurons.
[30]
A Heterologous Reporter Defines the Role of the Tetanus Toxin ...
CNTs are ∼150-kDa single-chain proteins which are cleaved into dichains that remain linked by an interchain disulfide bond (2). The dichain is composed of a ...Missing: tetanospasmin | Show results with:tetanospasmin
[31]
Interneuronal transfer and distal action of tetanus toxin and ...
The experiments reported here clearly establish that BoNT/A, BoNT/D, and TeNT undergo retrograde transport along axons, followed by cell-to-cell transfer of the ...
[32]
https://pmc.ncbi.nlm.nih.gov/articles/PMC4269290/
[33]
Clostridial Neurotoxins: Mechanism of SNARE Cleavage and ...
Apr 13, 2010 · This review summarizes the present knowledge about the molecular basis of the specific substrate recognition and cleavage mechanismMissing: tetanospasmin | Show results with:tetanospasmin
[34]
https://doi.org/10.1038/359832a0
[35]
https://pmc.ncbi.nlm.nih.gov/articles/PMC3153214/
[36]
Tetanus — Forgotten but Not Gone | New England Journal of Medicine
Mar 23, 1995 · The light chain is a zinc endopeptidase that cleaves an integral membrane protein of small synaptic vesicles, synaptobrevin, at a single site.
[37]
Tetanus Clinical Presentation - Medscape Reference
Feb 5, 2025 · Neonatal tetanus (tetanus neonatorum) is generalized tetanus that results from infection of a neonate. ... Patients often are afebrile.
[38]
Trismus - StatPearls - NCBI Bookshelf - NIH
Oct 27, 2022 · Trismus is commonly referred to as lockjaw and is usually due to sustained tetanic spasms of the muscles of mastication.
[39]
Tetanus Workup: Approach Considerations, Laboratory Studies ...
Feb 5, 2025 · The spatula test is a simple diagnostic bedside test that involves touching the oropharynx with a spatula or tongue blade. In normal ...Approach Considerations · Laboratory Studies · Spatula Test
[40]
Tetanus Toxoid IgG Antibody, Serum - Laboratory Test Directory
The diagnosis of tetanus is by clinical observation. A positive wound culture for the agent of tetanus, Clostridium tetani, may support, but does not confirm, ...
[41]
[PDF] Tetanus (Clostridium tetani) - Laboratory case definition
Broth cultures are tested for toxigenicity after incubation at 350C for 18-24 h; and, if negative, are re-tested after incubation for up to 4 days. 2.2.2 Test ...
[42]
Tetanus Antitoxoid | Test Detail | Quest Diagnostics
Antibody levels > or = to 0.10 IU/mL are considered protective. However, tetanus can still occur in some individuals with such antibody levels.
[43]
Tetanus Toxoid IgG Antibody - MLabs
A tetanus toxoid booster should strongly be considered for patients with anti-tetanus toxoid IgG values between 0.01 and 0.5 IU/mL. Some cases of tetanus, ...
[44]
TTIGS - Overview: Tetanus Toxoid IgG Antibody, Serum
Two to 3 weeks following vaccination, a patient's immunological response may be assessed by measuring the total antitetanus toxoid IgG antibody level in serum.Missing: antitoxin | Show results with:antitoxin
[45]
[Electromyography as a diagnostic aid in tetanus] - PubMed
However, the diagnosis can be performed by a simple and readily available electromyogram (EMG). We performed EMGs in 13 patients in whom tetanus was suspected ...
[46]
Case study Tetanus – A Rare But Real Threat - ScienceDirect.com
While literature on EMG in tetanus is limited, a Swiss study analyzed its use in patients posing a diagnostic dilemma and concluded that EMG is a reliable and ...
[47]
Tetanus Overlooked Due to the Involvement of Multiple Departments
Oct 31, 2023 · The diagnosis is based on clinical findings and not the result of specific blood and imaging tests; hence, it is very difficult to diagnose at ...Missing: CT | Show results with:CT
[48]
A Case of Cephalic Tetanus in an Elderly Patient with Trismus
Jun 26, 2018 · We report a delayed diagnosis of tetanus in an elderly female who presented with localized cephalic disease complicated by autonomic dysfunction and aspiration ...
[49]
Diphtheria Tetanus Pertussis (DTaP) Vaccine - StatPearls - NCBI - NIH
Mechanism of Action The DTaP vaccine is a combination of diphtheria, tetanus, and pertussis. It comprises diphtheria, tetanus toxoids (inactivated toxins), and ...Continuing Education Activity · Indications · Mechanism of Action · Adverse Effects
[50]
About Diphtheria, Tetanus, and Pertussis Vaccination | CDC
Each 0.5-mL dose of Td (MassBiologics) contains the following active ingredients: 2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid.
[51]
Child and Adolescent Immunization Schedule by Age (Addendum ...
Aug 7, 2025 · Birth to 15 Months ; Tetanus, diphtheria, & acellular pertussis · more info icon. (Tdap: ≥7 yrs). Human papillomavirus · more info icon. (HPV).
[52]
Adult Immunization Schedule Notes | Vaccines & Immunizations - CDC
Oct 7, 2025 · Routine vaccination · Completed primary series and received at least 1 dose Tdap at age 10 years or older: Td or Tdap every 10 years thereafter.
[53]
Fast Facts: Global Tetanus Vaccination - CDC
May 16, 2024 · Global tetanus vaccination programs reduced tetanus deaths in newborns by 95% in the last 30 years. Tetanus vaccination continues to decrease ...
[54]
Immunization coverage - World Health Organization (WHO)
Jul 15, 2025 · Coverage is estimated at 60% in countries using MenAfriVac in routine immunization programmes and 29% overall in the 26 countries. No case of ...
[55]
Tetanus Treatment & Management - Medscape Reference
Feb 5, 2025 · The CDC similarly recommends a 250 unit TIG dose IM for all patients with contaminated wounds and unknown or inadequate vaccination history.
[56]
Tetanus Prophylaxis - StatPearls - NCBI Bookshelf - NIH
Jan 23, 2023 · All tetanus prophylaxis should be used in conjunction with timely cleaning and debridement of wounds. Patients should receive immediate ...
[57]
Tetanus Vaccine Recommendations - CDC
Jun 10, 2025 · CDC recommends vaccination every 10 years for all adults to maintain protection against tetanus. Once an adult has received a dose of Tdap, ...Clinical Guidance for Wound... · ACIP Recommendations · Pertussis Vaccination
[58]
Clinical Guidance for Wound Management to Prevent Tetanus - CDC
Jun 10, 2025 · Healthcare providers shouldn't use antibiotics (topical or systemic) to try to prevent tetanus after a wound injury (potential tetanus exposure).
[59]
Tetanus - Infectious Diseases - Merck Manual Professional Edition
Diagnosis of Tetanus ... Antitoxin of animal origin is far less preferable because it does not maintain the patient's serum antitoxin level well and risk of serum ...
[60]
Analysis using a National Inpatient Database in Japan - ScienceDirect
Overall, 53.5% of the patients required intubation and mechanical ventilation. Among patients who required intubation and mechanical ventilation, 80.6% started ...Missing: statistics | Show results with:statistics
[61]
[PDF] Intensive Care Management of Severe Tetanus
1,2,13 Most patients with tetanus can tolerate large doses (sometimes up to 1000 mg/day) of diazepam without getting sedated.
[62]
Pharmacological management of tetanus: an evidence-based review
Mar 26, 2014 · Intravenous magnesium sulfate reduces muscle spasms and autonomic dysfunction but it may not be suitable as sole therapy to relieve spasms ...
[63]
Tetanus: Recognition and Management - PMC - PubMed Central
Important complications include laryngeal spasm, leading to airway obstruction and respiratory arrest; nosocomial infections; and sequelae of prolonged ...
[64]
Clinical Care of Tetanus - CDC
Jun 10, 2025 · Tetanus is a medical emergency requiring hospitalization, multiple medications, and supportive care.
[65]
Tetanus (Lockjaw) | Red Book - AAP Publications
Results of studies on the benefit from intrathecal administration of TIG are conflicting. The TIG preparation in use in the United States is not licensed or ...<|separator|>
[66]
Progressive localized tetanus in patient with inadequate human ...
May 3, 2021 · Localized tetanus is a rare form of tetanus and generally has a better prognosis, but it could become fatal when it progresses into generalized tetanus.<|separator|>
[67]
Tetanus - UpToDate
Sep 29, 2025 · Therefore, development of tetanus disease in humans requires the presence of three factors: lack of immunity (ie, inadequate vaccination), ...
[68]
Tetanus Medication - Medscape Reference
Feb 5, 2025 · The CDC does not recommend use of antibiotics for prophylaxis. However, they should be used in the case of apparent wound infection.
[69]
Intrathecal vs. intramuscular administration of human antitetanus ...
Intrathecal administration of ATS or TIG is more beneficial than intramuscular administration in the treatment of tetanus. Publication types. Comparative Study ...
[70]
Global epidemiology and burden of tetanus from 1990 to 2019
Apr 20, 2023 · In this study, the countries with high tetanus incidence were mainly distributed in Africa, South Asia, and Southeast Asia. As a preventable ...
[71]
Progress Toward Achieving and Sustaining Maternal and Neonatal ...
Mar 18, 2022 · During 2000–2020, 47 countries achieved elimination of MNT, reported neonatal tetanus cases decreased 88%, and estimated deaths declined 92%.
[72]
Global progress in neonatal tetanus elimination from 2000 to 2022
Jul 18, 2024 · By 2022, 86% of infants worldwide were protected at birth against tetanus, up from 74% in 2000. Neonatal tetanus cases decreased by 89% globally ...
[73]
Tetanus Surveillance and Trends - CDC
Jun 10, 2025 · Since 1947 reported tetanus cases have declined more than 95%. Reported deaths from tetanus have declined more than 99%.Key Points · How The Data Are Interpreted · Disease TrendsMissing: onset | Show results with:onset<|separator|>
[74]
Tetanus - Annual Epidemiological Report for 2021 - ECDC
Oct 25, 2023 · In 2021, 50 tetanus cases were reported in the EU/EEA, 10 of which were confirmed cases. The number of cases reported in 2021 was higher than that reported in ...
[75]
Tetanus in the Elderly: The Management of Intensive Care and ... - NIH
At present, approximately 100 cases of tetanus occur each year; 94% of the patients are ≥40 years of age and 18% of the patients are ≥80 years of age (2). A ...
[76]
Tetanus: Background, Pathophysiology, Etiology
Feb 5, 2025 · The median time interval between surgery and onset of tetanus was 7 days. Tetanus was reported after tooth extractions, root canal therapy ...
[77]
Update on Progress in Selected Public Health Programs After ... - CDC
Feb 20, 2015 · On January 12, 2010, an earthquake devastated Haiti's infrastructure, killing an estimated 230,000 persons and displacing more than 1.5 million ...
[78]
Global epidemiology and burden of tetanus from 1990 to 2019
As shown in Table S4, there were 370,885 incident cases of tetanus in 1990 and 27,171 cases in 2019 among newborns (aged 0-28 days) worldwide, which was also ...
[79]
[PDF] Protecting all against tetanus - World Health Organization (WHO)
Laboratory confirmation is not an aspect of NT surveillance, as the basis of tetanus diagnosis is clinical rather than laboratory-based. Case detection.
[80]
Global Impact of Tetanus - CDC
May 15, 2024 · Despite the success of vaccination, an estimated 14,000 infants still died of neonatal tetanus in 2019.1 These deaths occurred mainly in ...
[81]
Tetanus in Animals - Infectious Diseases - Merck Veterinary Manual
It may be possible to confirm the diagnosis by detecting tetanus toxin in serum from the affected animal. In cases in which the wound is apparent, verification ...
[82]
Tetanus in animals - PMC - PubMed Central - NIH
Feb 18, 2020 · Severely affected animals die of respiratory failure in 5–9 d. Although less susceptible to tetanus than horses and sheep, outbreaks of tetanus ...
[83]
Tetanus outbreak in a sheep flock due to ear tagging
Dec 13, 2018 · Tetanus is an acute, often fatal, infectious neuromuscular disease in all farmed mammals caused by Clostridium tetani.Introduction · Case presentation · Results · Discussion
[84]
Tetanus: A Storm Aftermath Problem for Animals - SDSU Extension
Jul 29, 2025 · Uncontrolled muscle contractions create clinical signs of stiffness, muscle tremors, a “sawhorse” stance and “flicking” of the third eyelid.
[85]
Tetanus in Horses - PetMD
Dec 19, 2022 · If a horse is unvaccinated for tetanus, the mortality (death) rate for horses is approximately 80%. If symptoms are caught early and your ...
[86]
Tetanus in horses: an overview of 70 cases - SciELO
High mortality rate (72.9%) was observed in this study. Forty (57.1%) horses presented history of wounds or surgical procedures related with tetanus, ...
[87]
Diagnosis and treatment of tetanus in cats and dogs
Jun 30, 2022 · The most susceptible species are horses, guinea pigs, monkeys, sheep, mice, goats and humans. Carnivores such as cats and dogs are less ...Missing: occurrence herbivores
[88]
Tetanus | Veterian Key
Oct 28, 2017 · In traumatized tissues with acidic pH due to local ischemia and anoxia, germination and C. ... tetani during the early steps of wound tetanus, ...<|control11|><|separator|>
[89]
Avian species, is it resistant to tetanus? - CABI Digital Library
In reality, the resistance of avian species to tetanus is due to a mutation at the cleavage site for a protein called VAMP (synaptobrevin). The VAMP is a ...
[90]
7 things you may not have known about tetanus - Equus Magazine
In contrast, chickens and other birds are highly resistant—a lethal dose is up to 300,000 higher per pound of body weight than for a horse. Likewise, it ...
[91]
The effect of tetanus toxin in the goldfish - PMC - PubMed Central
Tetanus toxin kills goldfish when administered in minute doses. The lethal effect is temperature dependent. Unlike mammals, in which tetanus toxin produces ...
[92]
Clostridium tetani - Pathogen Safety Data Sheets - Canada.ca
It is Gram positive in young cultures, but becomes Gram negative upon sporulation Footnote 1. It is catalase and superoxide dismutase negative. It produces a ...
[93]
[PDF] TETANUS
Oct 26, 2017 · Carnivores and birds are less susceptible. Cases can occur postpartum, or after surgical procedures, injuries or bites due to wound infection.
[94]
Tetanus: historical and palaeopathological aspects considering its ...
The muscles of the jaw contract by tightening the mouth (lockjaw), the forehead is typically wrinkled (tetanic facies), and the characteristic sardonic laugh ...
[95]
Chapter I - Diagnosis of diseases of nervous system
Feb 1, 2018 · The disease generally commences with shivering, horripilation, cloudiness of vision, upcoursing of the bodily Vayu and anesthesia, a pricking ...
[96]
Remembering Emil von Behring: from Tetanus Treatment to ...
Feb 28, 2017 · During the Franco-Prussian War (1870 to 1871) and the American Civil War (1861 to 1865), 350 tetanus cases with 90% mortality and 505 cases with ...
[97]
Ch-3 - Open Book Publishers
Nicolaier, in 1884, established that the infective organism was present in the soil. He produced the disease in mice, rabbits and guinea pigs by inoculation of ...
[98]
An excursion into pharmacology: curare in medicine - PMC
This may not be the complete list of references from this article. Cole L., Youngman H. Treatment of tetanus. Lancet. 1969 May 17;1(7603):1017–1019. doi ...
[99]
[PDF] Tetanus, Anti-tetanus Serum and the Royal Army Medical Corps in ...
Experimental, veterinary and clinical data suggested tetanus following contamination of wounds could be prevented by injecting anti-tetanus serum soon after ...
[100]
the 1890 Tetanus Antitoxin Paper of von Behring and Kitasato and ...
The significance of the 1890 tetanus antitoxin paper by von Behring and Kitasato in the development of a new discipline, immunology, is reviewed.
[101]
Emil von Behring: The founder of serum therapy - NobelPrize.org
Dec 3, 2001 · The development of an active vaccine took a few years. In 1913, Behring went public with his diphtheria protective agent, T.A. (Toxin-Antitoxin) ...
[102]
Studies on tetanus toxoid: I. Active immunization of allergic ...
Descombey. Tetanus Anatoxin. Compt. rend. Soc. de biol, 91 (1924), p. 239. Google Scholar. 5. G. Ramon, C. Zoeller. Tetanus Anatoxin and Active Immunization of ...
[103]
Vaccines for women for preventing neonatal tetanus - PubMed Central
Tetanus toxoid has been regarded as safe and useful since Descombey first reported its production in 1924 (Descombey 1924). Tetanus toxoid consists of a ...
[104]
Early U.S. Military Immunization Against Tetanus and Diphtheria - NIH
Aug 20, 2025 · Tetanus decreased dramatically, with only 12 tetanus cases (1 case per million) developing during the war, mostly in imperfectly immunized ...Missing: reduction | Show results with:reduction
[105]
Vaccine History: Developments by Year
Aug 21, 2023 · These three vaccines were combined in 1948 and given as the DTP vaccine. Late 1940s | Recommended Vaccines. Smallpox Diphtheria* Tetanus*First vaccines · The vaccine everyone was... · Vaccine development in the...
[106]
ACIP Recommends the Use of Tdap in Adults - AAFP
Sep 15, 2007 · In 2005, a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap; Adacel) was approved in the United States for ...Missing: introduction | Show results with:introduction
[107]
A Brief History of Vaccination - World Health Organization (WHO)
In 1974 the Expanded Programme on Immunization (EPI, now the Essential Programme on Immunization) is established by WHO to develop immunization programmes ...
[108]
Historical Comparisons of Morbidity and Mortality for Vaccine ...
Nov 14, 2007 · A greater than 92% decline in cases and a 99% or greater decline in deaths due to diseases prevented by vaccines recommended before 1980 were shown.<|control11|><|separator|>
[109]
Etymologia: Tetanus - CDC Stacks
From the Greek tetanos (“tension,” from teinein, “to stretch”), an often fatal infectious disease caused by the anaerobic bacillus Clostridium tetani.
[110]
Recombinant monoclonal antibody siltartoxatug versus plasma ...
Jul 8, 2025 · We conducted a randomized, double-blind, phase 3 trial to evaluate siltartoxatug—a first-in-class recombinant monoclonal antibody—for tetanus ...Missing: tetanospasmin | Show results with:tetanospasmin
[111]
Trinomab's Siltartoxatug Injection Achieves Landmark Publication in ...
Jul 8, 2025 · Siltartoxatug Injection—the world's first anti-tetanus monoclonal antibody—was developed using Trinomab's proprietary HitmAb® platform, a ...Missing: tetanospasmin | Show results with:tetanospasmin
[112]
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and ...
Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers.Missing: tetanospasmin | Show results with:tetanospasmin
[113]
Tetanus: Pathophysiology, Treatment, and the Possibility of Using ...
Here the toxin moves trans-synaptically into inhibitory nerve terminals, where vesicular release of inhibitory neurotransmitters becomes blocked, leading to ...Missing: recovery resynthesis regeneration
[114]
Early Treatment of Tetanus-Induced Trismus With Botulinum Toxin A
We conclude that botulinum toxin is effective in alleviating tetanus-induced trismus. It reduces the need for centrally acting muscle relaxants that may cause ...
[115]
Tetanus: pathophysiology, treatment, and the possibility of ... - PubMed
Jan 8, 2013 · Botulinum toxin may reduce tetanus symptoms. Trismus may be treated with botulinum toxin injections into the masseter and temporalis muscles.
[116]
Chronic Intrathecal Baclofen Administration for the Treatment of ...
Intrathecal baclofen adequately controlled her severe extensor spasms, facilitated her ventilatory management, and did not compromise her mental status during ...Missing: refractory | Show results with:refractory
[117]
Intrathecal baclofen use in the management of tetanus related spasm
We present a 12-years-old case diagnosed with tetanus and treated with ITB upon observation of spasms refractory to high dose sedation and muscle relaxants.
[118]
Ketamine in the management of generalised cephalic tetanus
Ketamine is of proven safety as an anaesthetic agent, especially in cases in which an anaesthetist is not readily available.
[119]
Tetanus | About the Disease | GARD
People living with rare diseases often face challenges such as delayed diagnosis, limited treatment options, and difficulty accessing knowledgeable providers.
[120]
A ten-year review of neonatal tetanus cases managed at a tertiary ...
Dec 7, 2021 · This study revealed that neonatal tetanus is still being seen in our clinical practice with poor outcome and the risk factors are the same as of old.
[121]
Tetanus - Immunization, Vaccines and Biologicals
The administration of Tetanus Toxoid Containing Vaccines (TTCVs) is the most cost-effective measure for preventing maternal and neonatal tetanus (MNT) as ...
[122]
Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein ...
Nov 28, 2023 · In this study, we evaluated 8MTT as a carrier for glycoconjugates and compared it to more traditional carrier proteins such as CRM197 and TT.<|separator|>
[123]
Thermostability of tetanus toxoid vaccine encapsulated in metal ...
Mar 28, 2025 · Accelerated stability studies were conducted at 40 °C and 60 °C using dried TT@ZIF-8 powder as well as two different liquid suspensions of TT@ ...
[124]
an overview on the mucosal vaccines and their adjuvants
Sep 30, 2022 · The aim of this review is to describe the mucosal immune system, as well as the potential for the development of vaccines and mucosal adjuvants, and their ...
[125]
Review Nanoparticle based oral delivery of vaccines: A promising ...
Aug 20, 2025 · In a phase 1 trial, oral vaccine tablets demonstrated successful induction of mucosal neutralizing IgA, supporting their efficacy. •. This ...
[126]
Update on Immunization and Pregnancy: Tetanus, Diphtheria, and ...
The recommended timing for maternal Tdap vaccination is between 27 weeks and 36 weeks of gestation. To maximize the maternal antibody response and passive ...
[127]
Multivalent mRNA-DTP vaccines are immunogenic and provide ...
Jun 10, 2024 · mRNA DTP immunized mice were also protected from pertussis toxin challenge as measured by prevention of lymphocytosis and leukocytosis.Missing: preclinical | Show results with:preclinical
[128]
[PDF] IMMUNIZATION AGENDA 2030 - World Health Organization (WHO)
Neonatal tetanus elimination (GVAP). Eliminate neonatal tetanus ... Reduce the numbers of cases and deaths from vaccine- preventable bacterial meningitis by 2030.Missing: projection | Show results with:projection